NFL Biosciences Advances Smoking Cessation Programs with Key Milestones
Event summary
- Post-hoc analysis of CESTO2 study data for NFL-101 completed, manuscript submission planned for October 2026.
- Regulatory decision on Phase 2 TONIC study for NFL-102 expected in November 2026.
- CEA preparing manuscript on brain imaging and proteomics results for submission in October 2026.
- Initial positive results from preclinical microdialysis study at McLean/Harvard received in late September 2026.
The big picture
NFL Biosciences is advancing its smoking cessation programs with key milestones in scientific publication and regulatory approval. The company's precision medicine approach for NFL-101 and the Phase 2 trial for NFL-102 position it within the growing biotech sector focused on addiction treatment. The strategic anomaly lies in the dual-track development of complementary immunotherapies, which could broaden its market appeal and licensing potential.
What we're watching
- Regulatory Approval
- Whether the ANSM and CPP will approve the Phase 2 TONIC study for NFL-102 in November 2026 as expected.
- Scientific Validation
- The impact of the upcoming scientific publications on licensing discussions for NFL-101.
- Clinical Efficacy
- The pace at which initial data from the TONIC study will provide insights into the safety and efficacy of NFL-102.
Related topics